The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Regulatory News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,032.00
Bid: 12,030.00
Ask: 12,034.00
Change: 4.00 (0.03%)
Spread: 4.00 (0.033%)
Open: 12,052.00
High: 12,094.00
Low: 12,018.00
Prev. Close: 12,028.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.5 (EPT/RI) Astrazeneca Plc

22 May 2014 10:41

RNS Number : 8133H
Morgan Stanley & Co. Int'l plc
22 May 2014
 

 

 FORM 8.5 (EPT/RI)

PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY

Rule 8.5 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Name of exempt principal trader:

Morgan Stanley & Co. International plc

(b) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

ASTRAZENECA PLC

(c) Name of the party to the offer with which exempt principal trader is connected:

 

ASTRAZENECA PLC

(d) Date dealing undertaken:

21 MAY 2014

(e) Has the EPT previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

Yes

 

2. DEALINGS BY THE EXEMPT PRINCIPAL TRADER

 

(a) Purchases and sales

 

 Class of relevant security

 Purchases/sales

 Total number of securities

 Highest price per unit paid/received

 Lowest price per unit paid/received

 USD 0.25 ORDINARY

 PURCHASES

 6,106

 495.6000 SEK

 484.0000 SEK

 USD 0.25 ORDINARY

 SALES

 9,233

 495.2000 SEK

 485.0000 SEK

 ADRS

 PURCHASES

 54,412.00 (Traded in ADR form)

 74.8220 USD

 73.6167 USD

 ADRS

 SALES

 54,412.00 (Traded in ADR form)

 74.8220 USD

 73.6167 USD

 

 

(b) Derivatives transactions (other than options)

 

 Class of relevant security

 Product description

e.g. CFD

 Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

 Number of reference securities

 Price per unit

 N/A

 N/A

 N/A

 N/A

 N/A

 

 

(c) Options transactions in respect of existing securities

 

(i) Writing, selling, purchasing or varying

 

 Class of relevant security

 Product description e.g. call option

 Writing, purchasing, selling, varying etc.

 Number of securities to which option relates

 Exercise price per unit

 Type e.g. American, European etc.

 Expiry date

 Option money paid/ received per unit

 USD 0.25 ORDINARY

 CALL

 SALE

 284,590

 4,150.0970

 E

 12/06/2014

 0.0071 GBP

 

(ii) Exercising

 

 Class of relevant security

 Product description e.g. call option

 Number of securities

 Exercise price per unit

 N/A

 N/A

 N/A

 N/A

 

(d) Other dealings (including subscribing for new securities)

 

 Class of relevant security

 Nature of dealing e.g. subscription, conversion

 Details

 Price per unit (if applicable)

 N/A

 N/A

 N/A

 N/A

 

The currency of all prices and other monetary amounts should be stated.

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(b), copy table 2(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

 

 

3. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the exempt principal trader making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

 

Details of any agreement, arrangement or understanding, formal or informal, between the exempt principal trader making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

 

Date of disclosure:

22 MAY 2014

Contact name:

Darren Wickert

Telephone number:

+44 (0)20 7425 6578

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERSEUSUEFLSEDI
Date   Source Headline
18th Jul 20167:00 amRNSTAGRISSO MET PRIMARY ENDPOINT IN PHASE III TRIAL
14th Jul 201612:07 pmRNSSecond Price Monitoring Extn
14th Jul 201612:02 pmRNSPrice Monitoring Extension
13th Jul 20167:00 amRNSAZ resolves Faslodex patent litigation in the US
1st Jul 20165:30 pmRNSTotal Voting Rights
28th Jun 20167:00 amRNSZavicefta approved in EU
23rd Jun 20167:00 amRNSAstraZeneca updates on Flumist vaccine in the US
14th Jun 20163:00 pmRNSDirector/PDMR Shareholding
9th Jun 20167:03 amRNSAZ agreement with Aspen for anaesthetics portfolio
3rd Jun 20167:00 amRNSAZ completes US licensing agreement with Ironwood
2nd Jun 20167:00 amRNSAZ LICENSES ZURAMPIC TO GRÜNENTHAL GMBH
1st Jun 201612:00 pmRNSBlock listing Interim Review
1st Jun 201611:30 amRNSTotal Voting Rights
27th May 201612:36 pmRNSPOSITIVE CHMP OPINION IN EU FOR SAXA/DAPA
27th May 20167:03 amRNSPositive results from AstraZeneca Faslodex trial
27th May 20167:00 amRNSAstraZeneca receives CRL from US FDA for ZS-9
23rd May 20164:00 pmRNSDirector/PDMR Shareholding
18th May 20167:00 amRNSTOP-LINE RESULTS FROM LYNPARZA GOLD TRIAL
17th May 20167:00 amRNSPOSITIVE BENRALIZUMAB RESULTS IN SEVERE ASTHMA
12th May 20167:00 amRNSSELUMETINIB GRANTED ORPHAN DRUG DESIGNATION IN US
11th May 20165:30 pmRNSPublication of Final Terms
9th May 20165:35 pmRNSLaunch and pricing of EUR2.2bn bond issues
5th May 20163:00 pmRNSPublication of a Prospectus
3rd May 20161:30 pmRNSTotal Voting Rights
3rd May 20167:01 amRNSAstraZeneca completes divestment of Imdur
3rd May 20167:00 amRNSAZ COMPLETES ACQUISITION OF TAKEDA RESPIRATORY
29th Apr 20165:30 pmRNSResult of AGM
29th Apr 201612:46 pmRNSPOSITIVE CHMP OPINION FOR CAZ AVI
29th Apr 20167:00 amRNSAZN: 1st Quarter Results
28th Apr 20169:00 amRNSNotice of Results
26th Apr 20169:29 amRNSAZ enters US licensing agreement with Ironwood
26th Apr 20167:01 amRNSBEVESPI AEROSPHERE APPROVED BY US FDA FOR COPD
8th Apr 20167:00 amRNSAZ TO CONTINUE PIVOTAL ALZHEIMER'S CLINICAL TRIAL
1st Apr 201611:30 amRNSTotal Voting Rights
29th Mar 20167:00 amRNSTAGRISSO APPROVED IN JAPAN FOR CANCER PATIENTS
24th Mar 20163:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20167:00 amRNSAZ reports results from Brilinta stroke trial
18th Mar 201610:30 amRNSNotice of AGM
8th Mar 20166:29 pmRNSFiling of Form 20-F with SEC
8th Mar 201612:00 pmRNSAnnual Financial Report
1st Mar 20162:30 pmRNSTotal Voting Rights
29th Feb 20161:45 pmRNSAZ REPORTS TOP-LINE RESULT OF TREMELIMUMAB TRIAL
29th Feb 20167:59 amRNSAZ enters licensing agreement with CMS for Plendil
26th Feb 201612:00 pmRNSDirector/PDMR Shareholding
25th Feb 20168:57 amRNSACALABRUTINIB ORPHAN DRUG DESIGNATION RECOMMENDED
19th Feb 20167:05 amRNSBRILIQUE APPROVED IN EU FOR HEART ATTACK PATIENTS
19th Feb 20167:00 amRNSZURAMPIC APPROVED IN EU FOR GOUT PATIENTS
17th Feb 20167:00 amRNSDurvalumab granted BTD by FDA for cancer patients
16th Feb 20168:01 amRNSNEW EXTERNAL BOARD APPOINTMENT
4th Feb 20167:00 amRNSAstraZeneca Full-Year and Q4 2015 Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.